



Current Agreements

Dealdoc

Asset purchase agreement for patent portfolio

Warner Chilcott
AGI Therapeutics

Jul 26 2011

Asset purchase agreement for patent portfolio

| | |
|---------------------------|---|
| Companies: | Warner Chilcott AGI Therapeutics |
| Announcement date: | Jul 26 2011 |
| Deal value, US\$m: | 0.3 : sum of transaction |

- [Details](#)
- [Financials](#)
- [Termsheet](#)
- [Press Release](#)
- [Filing Data](#)
- [Contract](#)

Details

| | |
|-------------------------------|--|
| Announcement date: | Jul 26 2011 |
| Industry sectors: | Bigpharma Pharmaceutical Specialty pharma |
| Therapy areas: | Gastrointestinal » Inflammatory bowel disease » Ulcerative colitis |
| Technology types: | Small molecules |
| Deal components: | Asset purchase |
| Stages of development: | Discovery Preclinical |
| Geographic focus: | Worldwide |

Financials

| | |
|---------------------------|--------------------------|
| Deal value, US\$m: | 0.3 : sum of transaction |
|---------------------------|--------------------------|

Termsheet

Warner Chilcott has completed the acquisition of a portfolio of patents from AGI Therapeutics for a purchase price of approximately \$0.3 million.

Press Release

Warner Chilcott Announces Acquisition of Patent Portfolio From AGI Therapeutics

DUBLIN, Ireland, July 26, 2011 (GLOBE NEWSWIRE) -- Warner Chilcott plc (Nasdaq:WCRX) today announced that it has completed the acquisition of a portfolio of patents from AGI Therapeutics plc for a purchase price of approximately \$0.3 million.

"We are pleased to have acquired the intellectual property rights to a novel early stage product under development for use in the treatment of gastrointestinal conditions, including ulcerative colitis," said Roger Boissonneault, President and CEO.

The Company

Warner Chilcott is a leading specialty pharmaceutical company currently focused on the women's healthcare, gastroenterology, dermatology and urology segments of the North American and Western European pharmaceuticals markets. The Company is fully integrated with internal resources dedicated to the development, manufacturing and promotion of its products. WCRX-G

CONTACT: Emily Hill Investor Relations 973-907-7084 Emily.Hill@wcrx.com

Filing Data

Not available.

Contract

Not available.